IL-23
FDA Approves Guselkumab for UC
The FDA has approved guselkumab (Tremfya, Janssen) for patients with moderately to severely active ulcerative ...
SEPTEMBER 12, 2024
Anti–IL-23 Agents Effective After Prior UC Treatment Failure
VANCOUVER, B.C.—Two different monoclonal antibodies targeting the interleukin-23 p19 subunit achieved all of ...
JANUARY 26, 2024
More Insight Into Anti-Interleukins
This month’s report focuses on the anti-interleukin treatments for inflammatory bowel disease, specifically ...
SEPTEMBER 21, 2023
Load more